Biotech News

Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology

Roivant (ROIV)RoivantClinical readout

At Week 16, 69% of participants receiving brepocitinib 45 mg achieved "Clear" or "Almost Clear" skin, with at least a 2-category improvement, compared with 0% receiving placebo Improvements in skin disease activity were evident as early as Week 4, increased over time, and were accompanied by

Related news

Roivant

Vant Operating Model Roivant develops and commercializes medicines through focused subsidiaries known as Vants. The structure gives individual programs dedicated teams while retaining access to the parent company's capital, development and commercialization capabilities. Brepocitinib Autoimmune Franchise Brepocitinib is an oral JAK1/TYK2...

Recent company news

Stock data

Close
38.96 USD
Market cap
20.32B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States